Menu Search
Equities

Japan Medical Dynamic Marketing Inc

JMD:FRA

Japan Medical Dynamic Marketing Inc

Actions
  • Price (EUR)3.60
  • Today's Change0.00 / 0.00%
  • Shares traded590.00
  • 1 Year change-11.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024 07:18 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Japan Medical Dynamic Marketing Inc had net income fall -10.68% from 1.42bn to 1.27bn despite a 8.78% increase in revenues from 21.31bn to 23.18bn. An increase in the cost of goods sold as a percentage of sales from 34.33% to 36.31% was a component in the falling net income despite rising revenues.
Gross margin63.41%
Net profit margin6.04%
Operating margin6.92%
Return on assets4.71%
Return on equity5.70%
Return on investment5.44%
More ▼

Cash flow in JPYView more

In 2024, cash reserves at Japan Medical Dynamic Marketing Inc fell by 483.38m. However, the company earned 2.10bn from its operations for a Cash Flow Margin of 9.08%. In addition the company used 1.80bn on investing activities and also paid 840.71m in financing cash flows.
Cash flow per share115.34
Price/Cash flow per share5.31
Book value per share942.48
Tangible book value per share935.70
More ▼

Balance sheet in JPYView more

Japan Medical Dynamic Marketing Inc has a Debt to Total Capital ratio of 8.95%, a higher figure than the previous year's 2.28%.
Current ratio4.82
Quick ratio1.82
Total debt/total equity0.0985
Total debt/total capital0.0895
More ▼

Growth rates in JPY

SmartText is unavailable
Div yield(5 year avg)0.82%
Div growth rate (5 year)9.24%
Payout ratio (TTM)26.30%
EPS growth(5 years)-8.46
EPS (TTM) vs
TTM 1 year ago		32.56
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.